Anti-aging supplement manufacturer ROKIT America (RKAM.US) applies for a US stock market IPO, aiming to raise $35 million.

ROKIT America (RKAM.US) is a supplier of anti-aging supplements spun off from South Korean company ROKIT Healthcare. The company submitted an application to the U.S. Securities and Exchange Commission (SEC) on Wednesday, planning to raise up to 35 million dollars through an initial public offering (IPO). The company researches and sells dietary supplements focused on cell health and aging-related health, with the main ingredient being -nicotinamide mononucleotide (NMN). Its flagship product combines NMN with other ingredients such as astragalus and resveratrol, selling as consumer health supplements in the U.S. and other global markets. In addition to its supplement business, the company is leveraging its parent company ROKIT Healthcare's technology to develop an artificial intelligence-driven organ regeneration platform, aimed at providing regenerative medicine applications in the future for the Americas market. The company's products are classified as dietary supplements and do not require FDA pre-approval. Based in Los Angeles, California, the company was founded in 2012 and generated $7 million in revenue in the 12 months ending on December 31, 2025. The company plans to list on the Nasdaq Stock Exchange under the ticker symbol "RKAM." ROKIT America submitted its listing application on October 2, 2025, in a confidential manner. Maxim Group LLC is the sole bookrunner for this offering.